The XXII NIBIT Meeting, scheduled to take placefrom October 23-25, 2025 in Livorno, is quickly approaching.
The XXII NIBIT Meeting will continue to be at the forefront of cancer immunology and immunotherapy,with a strong focus on clinical advancements across a variety of cancers.
As the field of Tumor Biotherapy continues to evolve, next year’s sessions will highlight cutting-edgedevelopments in human cancers such as non-small cell lung cancer (NSCLC), melanoma, hepatocellular carcinoma, gastrointestinal cancers, and breast cancer. These will include both established and emerging immunotherapy approaches.
Additionally, the meeting will delve into transformative technologies shaping the future of oncology,including AI-driven diagnostics, single-cell analysis, and spatial mapping of tumor microenvironments. These innovations aim to facilitate the development of personalized treatment strategies.
Now at its twenty-second edition, the annual NIBIT Meeting is among the most important scientific events in the field of immuno-oncology in Italy and Europe.
The emphasis on translational medicine, the interaction between clinicians and researchers, the attention to the most innovative research lines, the presence of international researchers, together with a rigorous independence from the industry, are the characteristics that make the NIBIT Meeting an essential event for all professionals (doctors, scientists, industry representatives, research nurses, data managers) involved in research and medicine in oncological immunotherapy.
